Mesa Laboratories Inc /Co/ (MLAB): who owns it and who trades it
As of Nov 16, 2026, MLAB insiders reported 7 open-market sales worth $1.6M and 5 purchases worth $1.4M in the last 12 months, with 16% of the sale value made under pre-set 10b5-1 plans. The largest seller was John James Sullivan (Director), with $800K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mesa Laboratories
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MLAB
159 funds and institutions reported MLAB shares worth $506M at the end of Q2 2026, about 92% of the company. The largest holder is Long Path Partners LP with 8.6%.
Funds and institutions (13F) 92%Everyone else 8%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Long Path Partners LP | 477,126 | 8.64% | $47.5M | +18% |
| BlackRock, Inc. | 440,552 | 7.97% | $43.9M | +12% |
| Boston Partners | 265,149 | 4.80% | $26.4M | -1% |
| Vanguard Capital Management LLC | 237,457 | 4.30% | $23.6M | +2% |
| AQR Capital Management LLC | 203,739 | 3.69% | $20.3M | +19% |
| Ranger Investment Management, L.P. | 173,988 | 3.15% | $17.3M | -14% |
| Morgan Stanley | 156,979 | 2.84% | $15.6M | -3% |
| Diamond Hill Capital Management, LLC (Investment Advisor) | 155,771 | 2.82% | $15.5M | +0% |
| Raymond James Financial Inc | 149,937 | 2.71% | $14.9M | +22% |
| Dimensional Fund Advisors LP | 148,395 | 2.69% | $14.8M | +19% |
| Geode Capital Management, LLC | 139,682 | 2.53% | $13.9M | +9% |
| Kennedy Capital Management LLC | 138,301 | 2.50% | $13.8M | -3% |
| Jacobs Levy Equity Management, Inc | 130,838 | 2.37% | $13M | +195% |
| State Street Corp | 124,292 | 2.25% | $12.4M | +2% |
| Russell Investments Group, Ltd. | 121,845 | 2.21% | $12.1M | -10% |
| Wasatch Advisors LP | 115,668 | 2.09% | $11.5M | +126% |
| Royce & Associates LP | 113,395 | 2.05% | $11.3M | -30% |
| Crawford Investment Counsel Inc | 98,805 | 1.79% | $9.8M | +3% |
| FMR LLC (Fidelity) | 88,857 | 1.61% | $8.8M | +1273% |
| D. E. Shaw & Co., Inc. | 81,755 | 1.48% | $8.1M | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MLAB insiders reported $1.4M of open-market purchases and $1.6M of sales. 16% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | John James Sullivan | Director | Sale | 7,093 | $112.80 | $800K | Form 4 |
| Aug 13, 2026 | Siddhartha Kadia | CEO | Purchase | 7,093 | $112.80 | $800K | Form 4 |
| Aug 13, 2026 | R Tony Tripeny | Director | Purchase | 900 | $113.69 | $102K | Form 4 |
| Jun 22, 2026 | Lyndsey Elizabeth Crennen | CAO | Sale | 442 | $89.50 | $39.6K | Form 4 |
| Jun 22, 2026 | Brian David Archbold | Vice president | Sale | 2,516 | $89.50 | $225K | Form 4 |
| Jun 22, 2026 | John Sakys | CFO | Sale | 2,827 | $89.50 | $253K | Form 4 |
| Jun 16, 2026 | Brian David Archbold | Vice president | Sale plan | 1,151 | $101.27 | $117K | Form 4 |
| Jun 16, 2026 | Lyndsey Elizabeth Crennen | CAO | Sale plan | 118 | $101.27 | $11.9K | Form 4 |
| Jun 16, 2026 | John Sakys | CFO | Sale plan | 1,223 | $101.27 | $124K | Form 4 |
| Mar 10, 2026 | Shiraz Shabanali Ladiwala | Director | Purchase | 3,500 | $72.23 | $253K | Form 4 |
| Mar 10, 2026 | Mark Christopher Capone | Director | Purchase | 1,301 | $76.35 | $99.3K | Form 4 |
| Mar 10, 2026 | R Tony Tripeny | Director | Purchase | 1,315 | $76.00 | $99.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| John James Sullivan | Director | – | $800K | Aug 13, 2026 |
| Siddhartha Kadia | President and CEO | $800K | – | Aug 13, 2026 |
| John Sakys | CFO | – | $377K | Jun 22, 2026 |
| Brian David Archbold | SVP Operations | – | $342K | Jun 22, 2026 |
| Shiraz Shabanali Ladiwala | Director | $253K | – | Mar 10, 2026 |
| R Tony Tripeny | Director | $202K | – | Aug 13, 2026 |
| Mark Christopher Capone | Director | $99.3K | – | Mar 10, 2026 |
| Lyndsey Elizabeth Crennen | CAO | – | $51.5K | Jun 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MLAB short interest
Moderate short interest. 6.7% of MLAB shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 62%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 377,163 MLAB shares were sold short, 6.7% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 80,558 shares, buying them all back would take about 4.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 377,163 | 6.74% | -3% | 80,558 | 4.7 |
| Oct 15, 2026 | 390,561 | 6.98% | -13% | 102,044 | 3.8 |
| Sep 30, 2026 | 447,048 | 7.99% | +11% | 120,938 | 3.7 |
| Sep 15, 2026 | 403,559 | 7.21% | -7% | 133,817 | 3.0 |
| Aug 31, 2026 | 433,982 | 7.76% | +28% | 159,824 | 2.7 |
| Aug 14, 2026 | 337,738 | 6.04% | +4% | 170,033 | 2.0 |
| Jul 31, 2026 | 324,102 | 5.87% | +18% | 129,676 | 2.5 |
| Jul 15, 2026 | 274,176 | 4.96% | -1% | 227,097 | 1.2 |
| Jun 30, 2026 | 276,170 | 5.00% | +15% | 208,767 | 1.3 |
| Jun 15, 2026 | 239,181 | 4.33% | -15% | 267,779 | 1.0 |
| May 29, 2026 | 279,822 | 5.06% | +21% | 210,603 | 1.3 |
| May 15, 2026 | 232,139 | 4.20% | +17% | 137,968 | 1.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mesa Laboratories company events
Mesa Laboratories filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, job cuts). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 13, 2026Job cutsAnnounced job cuts or other exit costs. Filing
- Sep 8, 2026VoteReported shareholder vote results. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 30, 2026RulesChanged its code of ethics. Filing
- Jun 15, 2026LeadershipThe board of directors of Mesa Laboratories, Inc. approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement described below. Filing
- May 27, 2026ResultsReleased financial results. Filing
- Mar 23, 2026LeadershipMesa Laboratories, Inc. announced the departure of Gary Owens as President and Chief Executive Officer of the Company, effective on or about April 13, 2026. Filing
- Mar 9, 2026LeadershipMesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President and Chief Executive Officer of the Company, effective on or about April 13, 2026. Filing
- Feb 3, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mesa Laboratories financials
Famous investors that hold MLAB
1 of the 50 well-known investors we track reported holding MLAB in their latest 13F filing. The largest position is Ken Griffin's, worth $556K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 4,278 | $556K | 0.0% | -88% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MLAB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.9% |
| Oct 9, 2026 | Wasatch Advisors LP | 13G | 6.9% |
| Oct 9, 2026 | Wasatch Advisors LP | 13G | 6.9% |
Questions about Mesa Laboratories Inc /Co/ (MLAB) stock
Who owns the most MLAB stock?
The largest reported owner of Mesa Laboratories Inc /Co/ (MLAB) is Long Path Partners LP, with 8.6% of the company. In total, 159 funds and institutions reported holding MLAB at the end of Q2 2026, together about 92% of the shares. See the largest owners.
Are MLAB insiders buying or selling?
In the last 12 months, MLAB insiders reported 5 open-market purchases worth $1.4M and 7 sales worth $1.6M. The latest trade was on Aug 13, 2026. See every trade.
What is the short interest in MLAB?
As of Oct 30, 2026, 377,163 MLAB shares were sold short, 6.7% of the shares outstanding, down 3.4% from the report before. At the average daily volume of 80,558 shares, buying them all back would take about 4.7 trading days (days to cover). See the history.
Which famous investors hold MLAB?
1 of the 50 well-known investors we track reported MLAB in their latest 13F filing, including Ken Griffin. The largest position is worth $556K. See all holders.
Executive pay
Mesa Laboratories's chief executive was paid a total of $6.6M for the year ended Mar 31, 2026, up 1% from $6.6M the year before. In the last 12 months, Mesa Laboratories's executives and directors bought $1.4M of stock on the open market and sold $1.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.